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EBER2 is an abundant nuclear noncoding RNA ex-
pressed by the Epstein-Barr virus (EBV). Probing its
possible chromatin localization by CHART revealed
EBER2’s presence at the terminal repeats (TRs) of
the latent EBV genome, overlapping previously iden-
tified binding sites for the B cell transcription factor
PAX5. EBER2 interacts with PAX5 and is required
for the localization of PAX5 to the TRs. EBER2 knock-
down phenocopies PAX5 depletion in upregulating
the expression of LMP2A/B and LMP1, genes near-
est the TRs. Knockdown of EBER2 also decreases
EBV lytic replication, underscoring the essential
role of the TRs in viral replication. Recruitment of
the EBER2-PAX5 complex is mediated by base-pair-
ing between EBER2 and nascent transcripts from the
TR locus. The interaction is evolutionarily conserved
in the related primate herpesvirus CeHV15 despite
great sequence divergence. Using base-pairing
with nascent RNA to guide an interacting transcrip-
tion factor to its DNA target site is a previously unde-
scribed function for a trans-acting noncoding RNA.
INTRODUCTION
Epstein-Barr virus (EBV) is a human lymphotropic gamma-1
herpesvirus (or lymphocryptovirus, LCV) that expresses two
noncoding RNAs called EBER1 (EBV-encoded RNA 1) and
EBER2, which are 167 and 173 nucleotides (nts) long, respec-
tively (Lerner et al., 1981). They are expressed during all forms
of EBV latency and also during lytic growth (Greifenegger
et al., 1998; Rowe et al., 2009). EBER1 accumulates to 106
and EBER2 to 2.5 3 105 copies per infected cell (Moss and
Steitz, 2013). The high copy number and the evolutionary con-
servation of EBERs in related primate LCVs point to a funda-
mental role of EBERs in the EBV life cycle (Howe and Shu,
1988; Rivailler et al., 2002b). To elucidate their function, recom-
binant EBV strains lacking EBERs have been engineered and
introduced into host B lymphocytes. However, conflicting obser-
vations regarding possible effects on B cell growth and transfor-
mation have been reported (Gregorovic et al., 2011; Swamina-
than et al., 1991; Yajima et al., 2005). Thus, the physiological
roles of EBERs have remained unclear. Likewise, only limitedmechanistic insights have been gained from investigating the
interacting partners of these noncoding RNAs. Both EBER1
and EBER2 bind the host RNA chaperone protein La (Lerner
et al., 1981), whereas ribosomal protein L22 and AUF1 (AU-
rich element binding factor 1)/hnRNP D (heterogeneous nuclear
ribonucleoprotein D) additionally associate with EBER1 (Lee
et al., 2012; Toczyski et al., 1994). A hallmark of EBV is its tumor-
igenic potential, and several EBV latent proteins have been
shown to contribute to oncogenicity (Young and Rickinson,
2004). Intriguingly, EBERs by themselves, particularly EBER1,
can cause tumors under certain conditions, but the exact molec-
ular mechanism has not been elucidated even though EBER1’s
interaction with L22 has been implicated in the process (Hou-
mani et al., 2009; Komano et al., 1999; Repellin et al., 2010).
The unidentified function(s) of EBERs must be confined to the
nucleus, as they exhibit strictly nuclear localization and do not
undergo nucleo-cytoplasmic shuttling (Fok et al., 2006).
The EBV genome in virions is linear, flanked on both ends by
tandem terminal repeats (TRs). These direct repeat units are
538 and 544 base pairs (bps) long (in EBV type I and II strains,
respectively) and contain high GC content (78%). Each viral
genome contains a varying number of up to 20 TRs (Brown
et al., 1988). Upon infection of a host cell, the viral genome circu-
larizes at the TRs, possibly through a recombination event, and
amplifies as multicopy episomes during latency (Lindahl et al.,
1976; Sugden et al., 1979). Following genome circularization,
the promoter region and exons of LMP2 (Latent Membrane Pro-
tein 2), located at opposite ends of the linear genome, become
juxtaposed to allow the expression of both LMP2A and LMP2B
isoforms, which differ by alternative promoter usage (Raab-
Traub and Flynn, 1986). Both isoforms modulate B cell receptor
signal transduction to prevent premature lytic reactivation (Miller
et al., 1994; Rovedo and Longnecker, 2007). During lytic replica-
tion, the circular EBV genome is amplified, giving rise to long
concatemers that are subsequently processed into unit length
genomes. Again, processing occurs in the TR region by a
proposed recombination event in conjunction with enzymatic
cleavage by a so-called terminase complex (Chiu et al., 2014;
Zimmermann and Hammerschmidt, 1995). The TRs further pro-
vide an essential sorting signal for the linear genome to be pack-
aged into capsids (Feederle et al., 2005). These observations un-
derscore the important role(s) of the TR regions in EBV genome
organization during both latency and the lytic cycle. The latency-
lytic switch is subject to tight regulation, as an expanding body of
evidence indicates that lytic replication contributes to oncogen-
esis (Katsumura et al., 2012; Ma et al., 2011).Cell 160, 607–618, February 12, 2015 ª2015 Elsevier Inc. 607
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Figure 1. EBER2 Localizes to the TRs of the EBV Genome
(A) Secondary structure model of EBER2. RNase H-sensitive regions (shown in B) are indicated in green. The region hybridizing to the ASO used in CHART is
underlined.
(B) Northern blot of EBER2 after RNase H digestion using DNA oligonucleotides complementary to EBER2. The numbers on top correspond to the nucleotides
targeted in EBER2. An arrow indicates the mobility of full-length EBER2 RNA. U6 RNA serves as a loading control.
(legend continued on next page)
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B lymphocytes are the major cell type infected by EBV. The
transcription factor PAX5 (Paired box protein 5) has been
described as a master regulator of B lymphocyte development
through promoting the expression of B cell specific genes and
repressing B-lineage inappropriate genes (Medvedovic et al.,
2011). Specific DNA binding of PAX5 is achieved through the
conserved paired box DNA-binding motif. Intriguingly, a recent
study has shown that PAX5 binds to the TRs of EBV, perhaps
to coordinate viral genome organization (Arvey et al., 2012).
PAX5 has further been shown to regulate EBV latent gene
expression, as depletion of PAX5 results, for example, in upregu-
lation of the expression of LMP1, the main transforming protein
of EBV that acts as a classical oncogene, and of both LMP2
isoforms (Arvey et al., 2012).
Here, we performed capture hybridization analysis of RNA tar-
gets (CHART) for EBER2, a method comparable to chromatin
immunoprecipitation (ChIP), but in CHART the chromatin locali-
zation of an RNA of interest is assayed (Simon et al., 2011). In lieu
of an antibody in ChIP experiments, CHART employs antisense
oligonucleotides (ASOs) that hybridize to accessible regions of
an RNA for selection (Figure S1). We report that EBER2 localizes
to the TRs of the latent EBV genome and provide in vivo evidence
that its recruitment involves an RNA-RNA interaction with
nascent RNA transcripts. This process in turn is required for effi-
cient association of PAX5 with its target sites within the TRs.
Perturbation of EBER2-PAX5 localization affects expression of
genes nearest its binding site as well as lytic viral DNA replica-
tion, with possible downstream effects on oncogenic processes.
RESULTS
EBER2 Co-Localizes with PAX5 to the TRs of the EBV
Genome
To identify an accessible region in EBER2 that could be targeted
by an ASO for selection in CHART (Simon et al., 2011), we added
30-nt-long DNA oligonucleotides complementary to EBER2 to
lysate from EBV-positive BJAB-B1 cells (which contain type II
EBV). Formation of DNA-RNA hybrids at accessible regions in
EBER2 induces cleavage by endogenous RNaseH. Two such re-
gions in EBER2 (nucleotides 47–70 and 101–124) were detected
by Northern blot analysis (Figures 1A and 1B). To select EBER2,
we therefore coupled to agarose beads an RNA ASO targeting
nucleotides 101–124, as the secondary structure of this region
is predicted to form an extensive loop (Figure 1A).
We then used CHART to identify EBER2 binding sites on
chromatin in the EBV-positive BJAB-B1 cell line; the isogenic
EBV-deficient BJAB cell line served as a negative control (Fig-
ure S1). Deep sequencing libraries from both cell lines were pre-
pared after CHART and subjected to Illumina massive parallel
sequencing. When the sequencing reads were mapped to the
host cell genome, no obvious EBER2 peaks were present in in-
fected BJAB-B1 cells compared to BJAB cells (data not shown).
However, prominent EBER2 binding sites mapped to the 30 end(C) EBER2-CHART results fromBJAB andBJAB-B1 cells. Deep sequencing reads
is plotted on the y axis. Several EBV genes and the C promoter region are indica
(D) EBER2-CHART peaks in the TR region (bracket in C) and the PAX5 ChIP pro
See also Figure S1 and Table S1.of the annotated EBV genome (Figure 1C, bottom, bracketed re-
gion). Since very few sequence reads from control BJAB cells
map to the EBV genome (Figure 1C, top), these peaks are un-
likely to represent host sequences that misalign with viral DNA.
A zoomed-in view shows that EBER2 localizes to the TR regions
of the EBV genome (Figure 1D, top), its profile strikingly overlap-
ping published ChIP data for the transcription factor PAX5 (Fig-
ure 1D). Because TRs represent tandem repeat sequences, as
for PAX5 (Arvey et al., 2012), we cannot distinguish whether
EBER2 binds to only one specific TR or whether it is equally
distributed across all TRs, as depicted here.
Given their co-localization on EBV chromatin, we asked
whether EBER2 and PAX5 interact with each other. Co-immuno-
precipitation after in vivo formaldehyde crosslinking using anti-
PAX5 antibody showed that EBER2 interacts with PAX5, while
EBER2 was not co-precipitated using an immunoglobulin G
(IgG) control antibody (Figures 2A and S2A). A reciprocal exper-
iment was performed using an EBER2 ASO (complementary
to nucleotides 101–124) that should select EBER2-associated
proteins. As shown by western blot analysis, PAX5 was enriched
by the EBER2 ASO, while a control ASO against EBER1 failed to
capture PAX5 (Figures 2B and S2B). We asked whether EBER2
interacts directly with PAX5 by performing an RNA immuno-
precipitation (IP) assay under denaturing conditions after UV
crosslinking (Lee et al., 2012). EBER2 did not precipitate with
anti-PAX5 antibody (Figure S2C), consistent with the fact that
EBER2 does not exhibit a band-shift in the presence of recom-
binant Pax5 in electrophoretic mobility shift assays (EMSAs)
(Figures S2D–S2G). Together, these results suggest that
EBER2 and PAX5 interact, but the association may be indirect.
Based on its interaction with PAX5, we reasoned that EBER2
might act in concert with PAX5 to regulate EBV-latent genes.
Therefore, we knocked down EBER2 using chimeric ASOs that
induce endogenous RNase H-mediated degradation (Table S1)
(Ideue et al., 2009) and assessed the mRNA levels of several
EBV-latent genes by qRT-PCR. Two knockdown ASOs (KD
ASOs) that target the available regions in EBER2 (nucleotides
101–124 and 39–62; Figures 1A and 1B) efficiently depleted
EBER2 to less than 20% of its original level upon nucleofection
(Figure 2D). As latent gene expression at 48 hr post-nucleofec-
tion did not change (data not shown), we introduced a second
KD ASO nucleofection step at 48 hr and harvested the cells after
3 days of depletion (Figure 2C). This procedure was necessary to
maintain EBER2 at less than 20% its original level because
EBER2 levels increased from 18% at 24 hr to 46% at 48 hr
after a single knockdown.
Upon EBER2 depletion, we observed that expression of
LMP2A, and to a lesser extent LMP1 and LMP2B, was upregu-
lated (Figure 2E), phenocopying the results of PAX5 knockdown
(Arvey et al., 2012). We observed no significant change for other
EBV genes (e.g., EBNA1 and BZLF1), as reported for PAX5
depletion (Arvey et al., 2012), possibly because we examined
the RNA levels at an earlier time point (after 3 days of EBER2weremapped to the entire EBV genome (x axis); the number of sequence reads
ted. White boxes for BZLF1 and LMP1 indicate reverse gene orientation.
file (from Arvey et al. 2012) are shown.
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Figure 2. EBER2 Interacts with PAX5 and Is Required for Efficient PAX5 Binding to TRs
(A) Northern blot of EBER2 after IP with IgG (control) or anti-PAX5 antibody after formaldehyde crosslinking (+FA). In, 5% input; S, 5% supernatant; IP, 100%.
(B) EBER1 and EBER2 ASOs were used to pull down associated proteins, followed by western blot using anti-PAX5 antibody (top). An arrow indicates PAX5; an
asterisk indicates a non-specific band. In, 10% input; S, 10% supernatant; B, 100% beads. The same samples were subjected to northern blot analysis to detect
EBER2 (bottom). Quantification of (A) and (B) are shown in Figures S2A and S2B.
(C) Experimental outline for EBER2 knockdown.
(D) Northern blot for EBER2 was carried out after EBER2 knockdown with two different KD ASOs (complementary to nucleotides 101–124 and 39–62) that target
the nucleotides indicated in green in Figure 1A. The same blot was probed for U6 as a loading control.
(E) RNA levels of several EBV genes were assessed by qRT-PCR after EBER2 knockdown.
(F) The LMP locus of the episomal EBV genome. LMP1 is transcribed in the opposite direction to LMP2. The variable number of TRs is indicated by (n).
(G) PAX5 localization at the TRs after EBER2 knockdown wasmeasured by ChIP-qPCR. The cellular CD79a promoter region, a known PAX5 target site, served as
a positive ChIP control. The Cpromoter region of the EBV genome (Cp), an active promoter region not bound by PAX5, was the negative control. All data represent
the mean of three independent experiments ± SD; **p = 0.008 (Student’s t test; n = 3).
See also Figure S2 and Table S1.depletion as compared to after 5 days of PAX5 depletion) in an
effort to reduce potential secondary effects of knockdown. Since
the TRs are located in the first intron of LMP2A/B, positioned
close to the transcription start site of LMP1 (Figure 2F), it is not610 Cell 160, 607–618, February 12, 2015 ª2015 Elsevier Inc.unexpected for these genes to be most affected by lack of
EBER2 localization to the TRs.
Finally, we asked whether EBER2 knockdown would affect
PAX5 recruitment to the TRs. As shown by PAX5 ChIP, EBER2
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Figure 3. PAX5 Is Dispensable for EBER2
Recruitment to the TRs
(A) Knockdown efficiency of PAX5 by lentivirally
expressed shRNAwas determined by western blot
using anti-PAX5 antibody. Anti-Nucleolin antibody
provided a loading control.
(B) qRT-PCR analysis after PAX5 knockdown.
(C) PAX5 ChIP-qPCR analysis after PAX5 knock-
down. *p = 0.03, **p = 0.002 (Student’s t test; n = 3).
(D) EBER2-CHART followed by qPCR analysis af-
ter PAX5 knockdown. All data represent the mean
of three independent experiments ± SD.
See also Table S1.depletion specifically reduced PAX5 localization at the TRs,
whereas its binding was unaltered at a cellular PAX5 target, the
CD79a promoter region (Figure 2G) (Revilla-I-Domingo et al.,
2012). In summary, our results show that EBER2 is required for
PAX5 recruitment to the TRs and synergizes with PAX5 to regu-
late certain EBV latent genes.
Base Pairing of EBER2 to Nascent LMP2 Transcripts
Recruits PAX5 to the TRs
The TR sequence in EBV DNA contains two strong PAX5
consensus sequences (Arvey et al., 2012), suggesting that
recruitment of the EBER2-PAX5 complex could be achieved
through the DNA binding domain of PAX5. To test whether
EBER2 is localized to the TRs by virtue of its interaction with
PAX5, we knocked down PAX5 using lentivirally expressed short
hairpin RNAs (shRNAs) as described previously (Arvey et al.,
2012). Efficient depletion of PAX5 in BJAB-B1 cells was con-
firmed by western blot (Figure 3A); the knockdown efficiency
(to40% of the original level) was sufficient to elicit upregulation
of LMP2A asmeasured by qRT-PCR (Figure 3B), arguing that the
transcriptional control imposed by EBER2-PAX5 was compro-
mised under these conditions. As expected upon depletion,
PAX5 localization assessed by ChIP was significantly reduced
at both the TRs and the CD79a promoter region (Figure 3C).
However, surprisingly, EBER2 localization at the TRs remained
unaffected as measured by CHART coupled to qPCR analysis
(Figure 3D). We conclude that EBER2 is required for PAX5 local-
ization (Figure 2G), but PAX5 is dispensable for EBER2 recruit-
ment to the TRs.
Since EBER2 appears to be the key recruiting entity of the
EBER2-PAX5 RNP, we considered the possibility of EBER2
recruitment via an RNA-RNA interaction. The fact that EBER2
binding to the TRs as assessed by CHART was not affected
when RNase H digestion preceded ASO selection argues
against an RNA-DNA interaction (Figures S3A and S3B). OnCell 160, 607–618,the other hand, a region within EBER2
that base pairs with an RNA transcribed
from the TR region, such as the nascent
transcripts of the two LMP2 isoforms,
which contain the TRs in their first intron,
might exist (Figure S4B). If this RNA-
RNA-mediated recruitment model were
correct, we should be able to (1) identify
the complementarity, (2) show that tran-scription through the TRs is required for EBER2 recruitment,
and (3) obtain evidence for a physical interaction between
EBER2 and the nascent TR sequence-containing transcript
in vivo.
Potential base pairing between EBER2 and the EBV type II TR
RNA sequence was examined using the RNAup program to
search for short, stable RNA-RNA interactions (Mu¨ckstein
et al., 2006). A putative 18-bp hybrid was identified with a pre-
dicted free energy of DG = 28.10 kcal/mol. This hybrid com-
prises EBV TR nucleotides 177–200 and EBER2 nucleotides
41–64 (Figure 4A). Intriguingly, this sequence in EBER2 coin-
cides with one of two oligonucleotide-accessible sites identified
by RNase H digestion (Figure 1B). Notably, the sequence within
the TR transcript (nucleotides 177–200) predicted to base pair
with EBER2 lies adjacent to one of the PAX5 consensus sites (nu-
cleotides 200–214; Figure 4A). A second putative 17-bp RNA-
RNA hybrid of comparable predicted stability was identified
that also overlaps with the same oligonucleotide-accessible re-
gion within EBER2 (site A versus site B of EBV type II; Figures
S5B–S5D).
To show that the accessible region in EBER2 (nucleotides 41–
64) is indeed necessary for its recruitment to TRs, we used an
antisense morpholino oligonucleotide (AMO) that anneals to
this region (AMOEBER2-1; Table S1; Figure 5A, left panel, nucle-
otides in blue) to block the putative EBER2-TRbase-pairing inter-
action. We analyzed mRNA levels for several EBV-latent genes
upon nucleofection of the 25-nt AMO EBER2-1 and observed
that LMP2A, and to a lesser extent LMP1 and LMP2B, transcripts
increased in level compared to a scrambled control AMO (AMO
CTRL) and an AMO targeting EBER2 nucleotides 146–170
(AMO EBER2-2; Table S1), which are not predicted to form
RNA-RNA interactions (Figures 4B and S3C). Moreover, AMO
EBER2-1 treatment reduced PAX5 localization specifically at
the TRs as measured by ChIP (Figure 4C). We were unable to
use an AMO against the TR nucleotides 177–200 to block baseFebruary 12, 2015 ª2015 Elsevier Inc. 611
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Figure 4. EBER2 Is Recruited to the TRs through Base Pairing with Nascent RNA from the TR Locus
(A) Predicted RNA-RNA interaction between EBER2 and a region within the TR (bottom). TR coordinates are also shown for the two PAX5 consensus sites (top).
(B) RNA levels of several EBV genes were measured by qRT-PCR after 3 days of treatment with EBER2 AMO complementary to nucleotides 35–59 (AMO EBER2-
1) or nucleotides 146–170 (AMO EBER2-2).
(C) Quantification of the PAX5 ChIP at the TR, Cp, and CD79a loci after treatment with AMO EBER2-1 or EBER2-2. The control IgG ChIP data (data not shown)
were comparable to those in Figure 2G. *p = 0.03 (Student’s t test, n = 3).
(legend continued on next page)
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A B
C
Figure 5. EBER2-Guided Recruitment of PAX5
to the TRs Appears to Be Evolutionarily
Conserved in a Related Gamma-Herpesvirus
(A) Secondary structure models of EBV EBER2 and
the EBER2 homolog of rhesus LCV (CeHV15). Nu-
cleotides predicted to base pair with TR RNA are
indicated in blue.
(B) Relative position and coordinates within the TR,
as well as the PAX5 consensus site, are shown (top).
The predicted RNA-RNA interaction between
CeHV15 EBER2 and the TR RNA is shown at the
bottom.
(C) Model for complementary base-pairing-mediated
recruitment of EBER2-PAX5 RNP to the TR region.
See also Figure S3.pairing of the nascent transcript with EBER2, as the nucleotide
sequence of this AMO exhibits strong self-complementarity
(data not shown). In summary, blocking the putative base-pairing
region of EBER2 with an AMO results in the same phenotype
as EBER2 depletion (Figures 2E and 2G). Importantly, CHART
confirmed decreased EBER2 binding to the TRs in the presence
of the AMO EBER2-1 that targets the predicted RNA-RNA inter-
action site (Figure 4D). These results argue that base pairing of
EBER2 to the nascent LMP2A/B transcript could be instrumental
in recruiting EBER2 and PAX5 to the TRs.
Todemonstrate that transcription through theTRs is necessary
for EBER2 recruitment, we interfered with LMP2 gene expres-
sion, which generates nascent transcripts containing TR se-
quences within the first intron (Figure 5C). We used CRISPR-
mediated transcriptional interference by the catalytically inactive
dCas9 protein to specifically silence both LMP2 isoforms (Gilbert
et al., 2013). We generated stable dCas9-KRAB-expressing
BJAB-B1 cells and identified potent single-guide RNAs (sgRNAs)(D) EBER2-CHART followed by qPCR analysis after AMO EBER2-1 or KD ASO treatment.
(E) qRT-PCR analysis after expressing sgRNAs targeting LMP2A and LMP2B (Figure S4B) in dCas9-KRA
(F) EBER2 CHART was conducted after CRISPR/dCas9-mediated transcriptional interference of LMP2 ge
(G) EBER2-RNP-containing cell lysate was incubated with an in-vitro-transcribed 42-nt RNA fragment from
pair with EBER2 as shown in (A). AMT was added where indicated, and the reaction was exposed to long-w
(254 nm) was included as indicated to reverse crosslinks. RNA was isolated, and northern blotting was
probing for EBER2 and the in-vitro-transcribed TR RNA. An arrow indicates EBER2 crosslinked to the TR
(H) EBV-positive cells were treated with long-wave UV light in the presence or absence of AMT. EBER1
together with co-precipitated RNAs, were reverse transcribed for qRT-PCR analysis. The abundance of TR
and EBER2-selected samples. Primers detecting 18S rRNA andGAPDHmRNAwere used as negative cont
experiments ± SD.
See also Figures S3 and S4 and Table S1.
Cell 160, 607–61against LMP2A and LMP2B (Figures 4E and
S4A–S4C). LMP1 expression was collater-
ally silenced by this approach, probably
because its promoter is located close to
the LMP2B transcription start site. Inhibiting
the expression of nascent transcripts
containing TR sequences by silencing both
LMP2 isoforms resulted in decreased
EBER2 binding to the TRs as determined
by CHART (Figure 4F). Simultaneous usage
of sgRNAs against both LMP2 isoforms
was necessary to observe decreasedEBER2 binding, as inhibiting one isoform alone did not affect
EBER2 localization to the TRs (Figure S4D; data not shown).
Finally, to confirm in vivo the predicted base-pairing interaction
between EBER2 and TR sequence-containing RNA, we used the
psoralen derivative aminomethyltrioxsalen (AMT). AMT preferen-
tially crosslinks pyrimidine bases on opposite strands of double-
stranded RNA after irradiation with 365 nm UV light; 254 nm UV
light irradiation reverses the crosslinks (Cimino et al., 1985). First,
we ascertained that AMT is able to crosslink the predicted inter-
action sites between EBER2 and nascent RNA containing the TR
sequence.We in vitro transcribed a 42-nt RNA from the TR region
(Table S1) that contains the sequence predicted to base pair with
EBER2andadded it to anEBER2RNPcontaining cell lysate.Only
in the presence of AMT and the in-vitro-transcribed TR RNA did
we observe a higher molecular weight band in an EBER2 North-
ern blot (Figure 4G, lane 4, arrow). This band disappeared when
crosslinks were reversed by irradiating with 254 nmUV light (Fig-
ure 4G, lane 6), indicating that the predicted base pairs formB-expressing BJAB-B1 cells.
nes. **p = 0.01 (Student’s t test, n = 3).
the TR region (nucleotides 167–208) predicted to base
ave UV light (365 nm). Short-wave UV-light irradiation
carried out on a denaturing urea-polyacrylamide gel,
RNA fragment.
and EBER2 were selected using specific ASOs and,
-sequence-containing RNA was measured in EBER1-
rols. All data represent themean of three independent
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Figure 6. EBER2 Depletion Results in
Decreased Viral Lytic Replication
(A) Viral lytic replication after KD-ASO-mediated
EBER2 depletion was measured by Southern blot
analysis using the Xho1.9 probe. The same blot
was probed for the cellular GAPDH locus as a
loading control.
(B) Experimental outline for viral lytic induction by
sodium butyrate (NaB) in combination with EBER2
knockdown by KD ASO.
(C) Quantification of three independent experi-
ments as shown in (A).
(D) Viral lytic replication was measured by qPCR
analysis, amplifying the EBV dyad symmetry DNA
region normalized to the cellular actin gene.
(E) Relative viral titer in supernatant was measured
by qPCR normalized to spike-in control. All data
represent the mean of three independent experi-
ments ± SD.
See also Figure S6 and Table S1.in vitro. In vitro crosslinking was also observed with the second
EBER2-TR interaction site (Figure S5E), suggesting that both
RNA-RNA interactions could contribute to association in vivo.
To show that base-pairing interaction does occur in vivo, we en-
riched EBER2, as well as EBER1 as a control, using ASO beads
under denaturing conditions from a lysate of cells after in vivo
psoralen crosslinking. EBERs, together with crosslinked RNAs,
were eluted from the ASO beads with tetraethylammonium chlo-
ride-containing buffer to minimize background (Figure S5A). TR
RNA was enriched by EBER2 compared to EBER1 ASO beads
only after psoralen crosslinking as measured by qRT-PCR (Fig-
ure 4H). No enrichment was observed for 18S rRNA or GAPDH
mRNA. Together, these results argue that EBER2 base pairs
with TR sequence-containing nascent transcripts of the LMP2A
and 2B genes in vivo.
EBER2’s Interaction with Nascent RNA Is Evolutionarily
Conserved
Of the many EBV-related primate LCVs (Lacoste et al., 2010),
complete genome sequences are available only for EBV (type I
and type II), for the rhesus (Cercopithecine herpesvirus 15,
CeHV15), and for the marmoset LCV (Callitrichine herpesvirus 3)
(Rivailler et al., 2002a, 2002b). The genome of the last has appar-
ently lost its EBER2 gene, while CeHV15 retains an EBER2 homo-
log. Even though only moderate sequence conservation (65%) is
exhibited, CeHV15EBER2 canbemodeled to fold into a structure
that is almost identical to that of EBV EBER2 (Figure 5A). The
CeHV15 TR, on the other hand, has no obvious sequence similar-
ity to the EBV TR sequence, except for high overall GC content
and a tandem repeat organization (Rivailler et al., 2002b); the
repeat unit is considerably longer (933bp) andcontains only a sin-
gle PAX5 consensus sequence (Figure 5B, top).
Using the RNAup program, we searched for an RNA-RNA
interaction between CeHV15 EBER2 and its TR sequence.
Only one stable hybrid was predicted with a free energy of
DG = 25.60 kcal/mol (Figure 5B, bottom). Strikingly, the
sequence within the CeHV15 EBER2 homolog predicted to
base pair with the TR is in the same relative location as is that
in EBV EBER2 (Figure 5A, nucleotides in blue). Furthermore,614 Cell 160, 607–618, February 12, 2015 ª2015 Elsevier Inc.despite great sequence divergence, the region within CeHV15
TR predicted to base pair with its EBER2 homolog overlaps
the PAX5 consensus site, similar to its position in the EBV TR
(compare Figure 5B and Figure 4A). Thus, the EBER2 guide func-
tion of PAX5 to the TRs appears to be evolutionarily conserved in
the rhesus virus and possibly other yet unsequenced LCVs.
EBER2 Knockdown Affects Viral Lytic Replication
Given the localization of EBER2 at the TRs, which during the lytic
cycle are the sites of viral genome linearization upon packaging
into capsids (Zimmermann and Hammerschmidt, 1995), we
asked whether viral lytic replication might be affected by
EBER2 depletion. We treated the replication-permissive EBV-
positive cell line HH514-16 with sodium butyrate (NaB) to induce
lytic replication in combination with EBER2 KD ASO nucleofec-
tion (Figures 6B and S6A) (Ragoczy et al., 1998). Genomic
DNA was isolated and subjected to Southern blot analysis using
the Xho1.9 probe, which covers a unique sequence adjacent to
the TR region, to quantify lytic replication (Figure S6B) (Raab-
Traub and Flynn, 1986). After EBER2 depletion, lytic replication
was decreased as analyzed by Southern blot and qPCR (Figures
6A, 6C, and 6D). The viral titer in the culturemediumwas reduced
to an even greater extent (Figure 6E). Depletion of PAX5 consis-
tently resulted in comparable decreased lytic replication (Figures
S6C–S6E), supporting the notion that EBER2 and PAX5 act in
concert. NaB promotes the expression of Zebra, an EBV tran-
scription activator encoded by the BZLF1 gene that acts to
induce lytic replication (Miller et al., 2007). EBER2 knockdown
did not affect Zebra expression (Figure S6F), ruling out the pos-
sibility that the decreased lytic replication was due to a lower
level of Zebra. Interestingly, the decrease in viral replication
was restricted to lytic replication, since latent replication,
measured in the absence of NaB induction (see Figure 2C),
was unaffected upon EBER2 knockdown (Figure S6G).
DISCUSSION
Using CHART, we identified EBER2 as localized to the TRs of
the latent EBV genome. We were unable to examine EBER1
localization by CHART because no region in EBER1 is accessible
for hybridization with an ASO (Lee et al., 2012). A potential func-
tion of EBER2 at the TRs was suggested by its chromatin co-
localization and interaction with the B cell master regulator
PAX5. Even though two strong PAX5 consensus sequences are
present in each TR unit, recruitment of the EBER2-PAX5 RNP
does not appear to be achieved by direct PAX5 binding to DNA
but is greatly facilitated by nucleotide sequence information
contributed by EBER2 (Figure 5C). Perhaps because of the
degenerate nature of the PAX5 consensus sequence (Fig-
ure S2D), the EBER2 RNP is required for efficient recruitment to
the DNA target site (Figure 2). Alternatively, the EBER2 RNP
may be required to clear adjacent chromatin of interfering fac-
tor(s) or to stabilize PAX5-DNA binding. We identified a base-
pairing interaction between EBER2 and nascent transcripts
from the TR regions that could provide such enhanced targeting
specificity (Figure 4A). Indeed, the process of transcription
through the TR regions per semight be integral to the recruitment
mechanism by opening the chromatin conformation and thus
facilitating accessibility of thePAX5-EBER2RNP to its target site.
We identified PAX5 as a novel EBER2-interacting protein,
prompted by the observation that this transcription factor and
the viral noncoding RNA co-localize at the TRs (Figure 1). The
interaction appears to be indirect, based on the negative results
of EMSAs and UV crosslinking experiments (Figures S2C–S2G).
We are currently attempting to further analyze the EBER2-PAX5
RNP, particularly focusing on the factor that bridges EBER2 and
PAX5. Depletion of either EBER2 or PAX5 exhibits overlapping
phenotypes, such as the upregulation of LMP genes (Figure 2E),
suggesting both a functional and a physical interaction of the two
factors. PAX5 depletion was reported to have a broader effect on
EBV-latent gene expression (Arvey et al., 2012) than we observe
here, which might be explained by the different time points and
methods used. While Arvey et al. (2012) achieved PAX5 knock-
down by lentiviral expression of shRNAs and gene expression
changes were examined after 5 days, we chose an earlier time
point (3 days) for analyzing gene expression upon EBER2 deple-
tion by KD ASOs in an effort to exclude secondary and pleio-
tropic effects of long-term PAX5 knockdown.
Our attempts to recapitulate EBER2-PAX5-guided transcrip-
tional silencing at EBV TRs in heterologous reporter systems
were unsuccessful. When the entire LMP2A locus, including
the TRs in its first intron, was cloned into a vector and expressed
together with EBER2 and PAX5 in B lymphocytes, no effect on
LMP2A expression was observed (Figure S3D). Similarly, incor-
porating TRs into the 30 end of a luciferase reporter gene was
also unresponsive to the presence of EBER2 and PAX5 (Fig-
ure S3E). Apparently, a nascent transcript from the TRs alone
is not sufficient for PAX5 recruitment through EBER2, and other
factors, possibly DNA elements, are necessary to establish a
silenced chromatin architecture.
PAX5 at the TRs appears to exert a function other than acting
as a classical transcription activator or a repressor, as is normally
found at promoters. The repeat organization of the TRs might be
a crucial aspect of the PAX5 localization mechanism and
perhaps also of function. Indeed, the related transcription fac-
tors, Pax3 and Pax9, have been reported to restrict RNA output
frommouse satellite repeat sequences by binding and recruitinghistone methyl transferases to silence repetitive DNA (Bulut-Kar-
slioglu et al., 2012). In another uninfected cellular context, Pax5
action has been reported to regulate the immunoglobulin heavy
chain (Igh) locus during VDJ recombination in pro-B cells (Ebert
et al., 2011). Parallels include (1) repeat regions bound by Pax5,
the so-called Pax5-activated intergenic repeat elements (PAIRs),
of which 14 are interspersed in the Igh locus, and (2) strikingly,
the existence of a noncoding RNA expressed from the Igh locus.
Expression of the RNA coincides with Pax5 binding to the PAIRs,
whereas at later times in B cell development when the RNA
ceases to be made, Pax5 localization is no longer detected. It
is tempting to speculate that the Igh noncoding transcript might
contribute to Pax5 recruitment similarly to the nascent transcript
emanating from the TR regions of EBV. Furthermore, Pax5 in-
duces chromatin condensation of the Igh locus (Fuxa et al.,
2004). If an analogous chromatin contraction occurs at the TRs
of the EBV genome, transcriptional upregulation of LMP genes
following perturbation of the EBER2-PAX5-mediated control
mechanismmight be explained by a looser chromatin conforma-
tion that facilitates transcription through the region.
Consistent with the possibility that genome organization is
regulated by the EBER2-PAX5 interaction, EBER2 depletion
does not result in immediate transcriptional upregulation of
EBV genes nearest to its binding site; changes become apparent
only after 3 days of knockdown. This observation suggests that
the genome organization at the TRs, once established, remains
stable unless the correct organization cannot be resumed
following genome replication and/or dilution of regulating factors
by knockdown. Importantly, we demonstrate that EBER2 deple-
tion affects viral lytic replication and propose that decreased lytic
replication might be a consequence of improper genome organi-
zation that hinders efficient replication. Perhaps, latent replica-
tion is not affected because the TRs contribute differently to
the replication of EBV episomes, compared to the production
of linear packaged virion DNA. It is of course possible that there
are additional consequences of EBER2 knockdown that we have
not assessed in this study. One such possibility, given the fact
that both EBER2 and lytic replication have been implicated in
promoting oncogenicity (Katsumura et al., 2012; Ma et al.,
2011), is an interplay between the function of EBER2 at the
TRs and the consequences of lytic replication on tumor forma-
tion. An indication that EBER2 could have function(s) in addition
to recruiting PAX5 to the TRs stems from the fact that more
EBER2 molecules are present than complementary TR binding
sites; in an infected cell, there are 2.5 3 105 EBER2 molecules
and up to 50 EBV episomes, each containing up to 20 TRs,
although each TR probably harbors multiple nascent transcripts.
On the other hand, the overabundance of EBER2 molecules
compared to the number of TR binding sites during latency could
be necessary to accommodate the massive increase in EBV
genome copy number, and hence TR binding sites, occurring
during viral lytic replication.
In recent years, more and more long noncoding RNAs
(lncRNAs), arbitrarily defined as >200 nucleotides in size, have
been shown to fulfill a diversity of cellular functions (Cech and
Steitz, 2014). In addition to post-transcriptional regulation, a
common theme is the interaction of lncRNAs with chromatin-
modulating factors to control gene expression (Huarte et al.,Cell 160, 607–618, February 12, 2015 ª2015 Elsevier Inc. 615
2010; Nagano et al., 2008; Tsai et al., 2010; Zhao et al., 2008).
Thus, lncRNAs have been proposed in theory to act as targeting
guides for effector proteins by base pairing with specific chro-
matin sites via RNA-RNA interactions, RNA-DNA interactions
(Gilbert et al., 2013), or triplex formation (Schmitz et al., 2010).
RNA-RNA interactions are the best-supported interaction
mode experimentally for noncoding RNAs smaller than 200 nu-
cleotides, as exemplified by small nucleolar RNAs acting in
RNA modification, small nuclear RNAs in pre-mRNA splicing,
or microRNAs in targeting mRNAs (Kim et al., 2009; Watkins
and Bohnsack, 2012;Will and Lu¨hrmann, 2011). A guide function
for targeting specific sites on chromatin thus far has been
ascribed to tiny RNAs only, such as piwi-interacting RNA-medi-
ated recruitment of PIWI in Drosophila, small-interfering-RNA
(siRNA)-mediated centromeric silencing in yeast, and siRNA-
directed DNA methylation in plants (Lejeune et al., 2010; Malone
and Hannon, 2009; Matzke et al., 2007). All previously reported
lncRNAs appear to fulfill an architectural scaffolding function,
often with chromatin-regulating proteins. Here, for the first
time, we provide evidence for a base-pairing interaction of a
trans-acting moderately sized noncoding RNA, EBER2, which
facilitates the recruitment of an associated transcription factor
to chromatin target sites.
The ability of EBER2 to help recruit PAX5 to the TRs appears
to be evolutionarily conserved not only in both type I and type
II EBV (Figures S5B–S5E) but also in a related rhesus LCV.
Marmoset LCV, a virus that infects a new world primate, has
lost an EBER2 homolog but nonetheless retains a strong PAX5
consensus site within its TR (Rivailler et al., 2002a), suggesting
that PAX5 binding occurs. This raises the question of whether
PAX5 is recruited by an analogous mechanism involving a yet
unidentified noncoding RNA, which has replaced EBER2, or
whether a compensatory mechanism not involving an RNA-
RNA interaction mediates recruitment of PAX5 in marmoset
LCV. A better understanding of the precise EBER2-PAX5 RNP
composition will be essential to distinguish between the two
possibilities. Another open question is whether EBER2 is re-
cruited to TRs in EBV-infected cells that do not express the B-
cell-specific factor PAX5, such as nasopharyngeal carcinoma
(NPC) cells, which are epithelial. As NPCs exhibit latency II
(Rowe et al., 2009), characterized by robust expression of
LMP1 and LMP2 genes, as well as EBER2, EBER2-PAX5-medi-
ated transcription inhibition is unlikely to occur in these cells.
Similarly, the questions of whether and how PAX5 is recruited
to the TRs in EBV strains carrying a deletion of the EBER2
gene also remain to be answered.EXPERIMENTAL PROCEDURES
CHART Assay
Endogenous RNase H cleavage assays were performed as described in Lee
et al. (2012). CHART was carried out as described in Simon (2013), with minor
modifications. CHART-seq data were deposited in the Sequence Read
Archive under the accession number SRR1640963. For detailed protocols,
see the Extended Experimental Procedures.
EBER2 and PAX5 Knockdown
2.5 3 106 BJAB-B1 cells were nucleofected with 10 ml of 100 mM KD ASO/
AMO stock solution in SF solution with program EN-150 using the Lonza616 Cell 160, 607–618, February 12, 2015 ª2015 Elsevier Inc.4D-Nucleofector System. HH514-16 cells were nucleofected using the Lonza
2b Device with solution V and program A-023. On the day following nucleofec-
tion, cells were separated from debris using Lymphocyte Separation Medium
(Corning Cellgro) in accordance with the manufacturer’s instructions. For KD
ASO and AMO sequence information, see Table S1. KD ASOs were designed
(Ideue et al., 2009) with DNA nucleotides flanked by 20-O-methyl nucleotides
and consisting of a phosphorothioate backbone (for increased stability) to
induce cleavage by endogenous RNase H.
RNAi against PAX5 was performed by lentiviral shRNA expression using
MISSION shRNA clones TRC0000016061 and TRC0000016062 (SIGMA) as
described previously (Arvey et al., 2012; Cozma et al., 2007). Lentiviruses
were produced as described previously (Lee et al., 2012). Cells were cultured
under puromycin selection 1 day after infection and harvested 4 days post-
infection, as a decrease in proliferation rate became apparent at this time
point.
Psoralen Crosslinking of RNAs
A 42-nt or 36-nt RNA within the TR region (nucleotides 167–208 and 74–109 of
EBV type II, respectively) predicted to base pair with EBER2 was in vitro tran-
scribed with T7 polymerase from an oligonucleotide template (see Table S1 for
sequence). For psoralen crosslinking of EBER2 RNP to the in-vitro-transcribed
TR fragment, nuclei were isolated by lysing 107 BJAB-B1 cells in 10 mM Tris
(pH 8.0), 0.32 M sucrose, 3 mM CaCl, 0.1 mM EDTA, and 0.1% NP-40 and
were then resuspended in 100 ml of 10 mM HEPES (pH 7.4), 150 mM KCl,
5 mMMgCl2, 0.2 mMDTT, 10% glycerol, and 0.5%NP-40 to generate nuclear
extract. The lysate was cleared by a 3-min centrifugation step at full speed in a
table-top centrifuge. 200 ng of in-vitro-transcribed TR fragment was added to
10 ml of nuclear extract in the presence of 40 mg/ml aminomethyltrioxsalen
(AMT), 0.2 mg tRNA, and 40 U RNase inhibitor and incubated 30 min at room
temperature (RT) before the reaction was irradiated for 30 min on ice covered
with a 2-mm-thick glass plate from a distance of 2.5 cm with a handheld 365-
nm UV lamp. Extracts were treated with 254-nm UV irradiation for 10 min on
ice, where applicable. After crosslinking, RNA was isolated with TRIZOL and
subjected to Northern blot analysis.
For in vivo crosslinking of intact cells, 23 107 cells were resuspended in 1ml
of growth medium containing 50 mg/ml AMT, incubated for 5 min at 37C
before chilling the cells on ice, and irradiated with UV light as described above.
Cells were washed with PBS, and RNA was isolated with TRIZOL and DNase
treated. 20 mg total RNA was heated in 100 ml TE buffer at 95C for 3 min and
chilled on ice before 50 ml Denaturant buffer and 150 ml 23Hybridization buffer
were added (see CHART protocol above). 25 ml of biotinylated (EBER1 or
EBER2) ASO-streptavidin Dynabeads were added and incubated overnight
at RT. Beads were washed three times with CHART wash buffer and once
with 2.4 M tetraethylammonium chloride (TEACl) at 25C, and bound RNAs
were eluted with 2.4M TEACl for 5min at 40C, followed by phenol-chloroform
extraction prior to Northern blot or qRT-PCR analyses.
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